Overview

A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)

Status:
Recruiting

Trial end date:
2023-02-10

Target enrollment:

Participant gender:

Summary

This is a study of tirzepatide in Chinese participants without Type 2 Diabetes who have obesity or overweight. The main purpose is to learn more about how tirzepatide affects body weight.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

LY3298176
Tirzepatide